Cumberland Pharmaceuticals (CPIX) Gross Margin (2010 - 2026)

Cumberland Pharmaceuticals has disclosed Gross Margin across 17 years of filings, most recently posting 78.82% for Q1 2026.

• Gross Margin for Q1 2026 came in at 78.82%, up 1495.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 94.86% (down 258.0% YoY), and the FY2025 annual result was 85.02%, up 242.0% from the prior year.
• Gross Margin came in at 78.82% for Q1 2026 at Cumberland Pharmaceuticals, down from 145.49% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 159.55% in Q4 2024 to a low of 11.72% in Q4 2022.
• The 5-year median for Gross Margin is 78.82% (2026), against an average of 74.12%.
• Across the five-year window, Gross Margin tumbled 7198 bps in 2022 and surged 9536 bps in 2023, its largest moves.
• Cumberland Pharmaceuticals' Gross Margin stood at 11.72% in 2022, then surged by 814 bps to 83.64% in 2023, then surged by 91 bps to 159.55% in 2024, then decreased by 9 bps to 145.49% in 2025, then slumped by 46 bps to 78.82% in 2026.
• The last three Gross Margin figures came in at 78.82% (Q1 2026), 145.49% (Q4 2025), and 46.53% (Q3 2025), per Business Quant data.